Results 51 to 60 of about 19,752 (209)

Burosumab therapy in children with x-linked hypophosphatemia [PDF]

, 2018
BACKGROUND X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities.
Boot, Annemieke M, Carpenter, Thomas O, Chen, Chao-Yin, Hogler, Wolfgang, Imel, Erik A, Kakkis, Emil, Linglart, Agnes, Mao, Meng, Martin, Javier San, Padidela, Raja, Portale, Anthony A, Skrinar, Alison, van\u27t Hoff, William, Whyte, Michael P   +13 more
core   +2 more sources

Phosphaturic mesenchymal tumor: Clinicopathological features with outcomes in 10 patients with review of literature

Indian Journal of Pathology and Microbiology
Background: Phosphaturic mesenchymal tumors (PMTs) are rare mesenchymal tumors, associated with long-standing, non-specific but often debilitating symptoms in the affected patients.
Vivek C. Parameshwar, Bharat Rekhi, Ashwini Duggad, Mukta Ramadwar   +3 more
doaj   +1 more source

An Unusual Combination of Neurological Manifestations and Sudden Vision Loss in a Child with Familial Hyperphosphatemic Tumoral Calcinosis [PDF]

, 2019
Hyperphosphatemia in the absence of renal failure is an unusual occurrence, particularly in children, but is a common primary feature of familial hyperphosphatemic tumor calcinosis.
Acton, Dena, Evans, Michael J., Gray, Amie K., Ichikawa, Shoji, Kekunnaya, Ramesh, Lingappa, Lokesh, Madarasu, Rajsekara Chakravarthi, Siddaiahagari, Sirisharani   +7 more
core   +1 more source

FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease [PDF]

, 2020
Background: The aim of our study was to evaluate the relevance of FGF23-klotho axis in the predisposition for bone fractures in type 2 diabetic patients with early chronic kidney disease.
Ana Luísa Ribeiro, Ana Paula Silva, Bacchetta, Bernheim, Block, Daya, Desjardins, Ducy, Ducy, Eduarda Carias, Ferron, Filipa Mendes, Fliser, Fátima Rato, Gutiérrez, Hill, Hu, Isakova, Isakova, Jovanovich, Kazama, Lane, Lee, Levey, Manghat, Mirza, Mirza, Moayeri, Moreno, Moseley, Nélio Santos, Pedro Leão Neves, Pi, Pinkau, Qu, Quarles, Ray, Sanches, Sellmeyer, Shimada, Silva, Silva, Silva, Sitara, Stubbs, Titan, Torres, Urakawa, Wallace, Wang, Wolf, Yilmaz, Zimering   +52 more
core   +1 more source

Novel early markers of chronic kidney disease

Pediatria i Medycyna Rodzinna, 2019
Chronic kidney disease is an irreversible kidney damage caused by structural or functional renal impairment and persisting for more than 3 months. It is usually accompanied by albuminuria, proteinuria, abnormal histopathological and imaging findings as ...
Anna Bujnowska, Agata Będzichowska, Katarzyna Jobs, Bolesław Kalicki   +3 more
doaj   +1 more source

Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. [PDF]

, 2015
Osteocytes regulate bone turnover and mineralization in chronic kidney disease. As osteocytes are derived from osteoblasts, alterations in osteoblast function may regulate osteoblast maturation, osteocytic transition, bone turnover, and skeletal ...
Bowen, Richard E, Delany, Anne M, Freymiller, Earl G, Khouzam, Nadine M, Pereira, Renata C, Salusky, Isidro B, Wesseling-Perry, Katherine   +6 more
core   +2 more sources

Clinical Profile and Treatment Outcomes of Tumour-Induced Osteomalacia – A Single-Centre Experience

Indian Journal of Endocrinology and Metabolism
Introduction: Tumour-induced osteomalacia (TIO) is rare. At our referral centre, we see a substantial number of TIO. Therefore, we planned to study their profile and treatment outcomes to provide insight in management.
Prashiddha Dhakal, Alpesh Goyal, Viveka P. Jyotsna, Ashutosh K. Arya, Devasenathipathy Kandasamy, Shipra Agarwal, Madhvi Tripathi, Mani Kalaivani, Rajesh Khadgawat, Nikhil Tandon   +9 more
doaj   +1 more source

FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice

JCI Insight, 2023
Fibroblast growth factor 23 (FGF23) is a phosphate-regulating (Pi-regulating) hormone produced by bone. Hereditary hypophosphatemic disorders are associated with FGF23 excess, impaired skeletal growth, and osteomalacia. Blocking FGF23 became an effective
Guillaume Courbon, Dominik Kentrup, Jane Joy Thomas, Xueyan Wang, Hao-Hsuan Tsai, Jadeah Spindler, John Von Drasek, Laura Mazudie Ndjonko, Marta Martinez-Calle, Sana Lynch, Lauriane Hivert, Xiaofang Wang, Wenhan Chang, Jian Q. Feng, Valentin David, Aline Martin   +15 more
doaj   +1 more source

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Toxins, 2020
Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis.
Merita Rroji, Andreja Figurek, Goce Spasovski   +2 more
doaj   +1 more source

A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. [PDF]

PLoS ONE, 2012
Elevations of circulating Fibroblast growth factor 23 (FGF23) are associated with adverse cardiovascular outcomes and progression of renal failure in chronic kidney disease (CKD).
Bing Dai, Valentin David, Aline Martin, Jinsong Huang, Hua Li, Yan Jiao, Weikuan Gu, L Darryl Quarles   +7 more
doaj   +1 more source